Evidence map›Paper›PMID 40582699›Full record

ArticleJournal of thrombosis and haemostasis : JTH2025

Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis.

Robert Silasi, Ravi S Keshari, Tomohiro Abe, Stephanie D Byrum, Girija Regmi, Cristina Lupu, Constantin Georgescu, Joe H Simmons, Aleksandr Shamanaev, Samantha A Moellmer and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Robert SilasiCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
Ravi S KeshariCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
Tomohiro AbeCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
Stephanie D ByrumDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Girija RegmiCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
Cristina LupuCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
Constantin GeorgescuCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
Joe H SimmonsMichale E. Keeling Center for Comparative Medicine and Research, University of Texas MD Anderson Cancer Center, Bastrop, Texas, USA.
Aleksandr ShamanaevAnthos Therapeutics, Cambridge, Massachusetts, USA.
Samantha A MoellmerDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, USA.
Cristina PuyDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, USA.
Joseph J ShatzelDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, USA.
Dennis ProvinceDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Rick D EdmondsonDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Samuel G MackintoshDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Nathan L AvarittDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Dan BloomfieldAnthos Therapeutics, Cambridge, Massachusetts, USA.
David GailaniDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Alan J TackettDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Owen J T McCartyDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, USA.
Florea LupuCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA. Electronic address: Florea-Lupu@omrf.org.

Funding

Specific Pathogen Free Baboon Research Resource (SPFBRR) - Bridge Funding Administrative SupplementP40OD024628 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WILLIAM D HOPKINS · 2017 to 2026
$15.7M
Supplement for Google cloud build-outR24GM137786 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Alan Tackett · 2020 to 2026
$15.4M
Biochemistry and Pathophysiology of Factor XI and Contact ActivationR35HL140025 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GAILANI, DAVID · 2018 to 2024
$5.5M
Contact Activation and InfectionR01AI157037 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI LUPU, FLOREA, MCCARTY, OWEN J · 2020 to 2024
$3.3M
Complement C5 inhibition as sepsis therapyR01AI168355 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI FLOREA LUPU · 2022 to 2026
$3.2M
Discovery and Characterization of Novel Sepsis Proteome BiomarkersR01GM141040 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI LUPU, FLOREA, TACKETT, ALAN · 2021 to 2024
$2.2M
NHLBI NIH HHS R35 HL140025NIAID NIH HHS R01 AI157037NIAID NIH HHS R01 AI168355NIGMS NIH HHS R01 GM141040NIGMS NIH HHS R24 GM137786NIH HHS P40 OD024628
6 · The paper itself

Abstract

backgroundSepsis remains a major clinical challenge characterized by dysregulated immune response, coagulation abnormalities, and multiorgan failure, leading to high morbidity and mortality.

objectivesThis study investigated the therapeutic potential of abelacimab, a monoclonal antibody targeting the plasma zymogen factor (F)XI, in a new baboon model of Staphylococcus aureus sepsis.

methodsHealthy Papio anubis baboons were randomly assigned to control or abelacimab treatment groups. Both groups (n = 6, each) were intravenously infused with a median lethal (LD

resultsAll 6 abelacimab-treated baboons survived until the 7-day endpoint, while 3 out of 6 untreated controls succumbed to sepsis within 102 hours. Abelacimab significantly attenuated sepsis-induced coagulopathy without signs of bleeding, as evidenced by biochemical tests and pathology analysis. Treated animals exhibited decreased proinflammatory cytokines, diminished neutrophil activation, and preservation of endothelial integrity, collectively conferring robust protection against organ damage. Proteomic analysis revealed that abelacimab modulated pathways related to coagulation, inflammation, and tissue injury, contributing to improved survival outcomes.

conclusionFXI inhibition by abelacimab offers significant protection by attenuating activation of coagulation, reducing inflammation, and preventing organ failure. Targeting FXI may be a promising therapeutic strategy for managing sepsis by addressing multiple facets of its complex pathophysiology.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedFactor XISepsisStaphylococcal InfectionsStaphylococcus aureusAnimalsBlood CoagulationDisease Models, AnimalInflammation MediatorsPapioPapio anubisTime FactorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedFactor XIInflammation Mediatorsabelacimabfactor XIproteomicssepsisStaphylococcus aureus

Identifiers

PMID40582699
PMCPMC12668790

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.